<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32973290</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Inducible EphA4 knockout causes motor deficits in young mice and is not protective in the SOD1<sup>G93A</sup> mouse model of ALS.</ArticleTitle><Pagination><StartPage>15713</StartPage><MedlinePgn>15713</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">15713</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-72723-y</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by motor neuron loss that ultimately leads to fatal paralysis. Reducing levels or function of the tyrosine kinase, ephrin type-A receptor 4 (EphA4), has been suggested as a potential approach for slowing disease progression in ALS. Because EphA4 plays roles in embryonic nervous system development, study of constitutive knockout (KO) of EphA4 in mice is limited due to confounding phenotypes with homozygous knockout. We used a tamoxifen-inducible EphA4 conditional KO mouse to achieve strong reduction of EphA4 levels in postnatal mice to test for protective effects in the SOD1<sup>G93A</sup> model of ALS. We found that EphA4 KO in young mice, but not older adult mice, causes defects in muscle function, consistent with a prolonged postnatal role for EphA4 in adolescent muscle growth. When testing the effects of inducible EphA4 KO at different timepoints in SOD1<sup>G93A</sup> mice, we found no benefits on motor function or disease pathology, including muscle denervation and motor neuron loss. Our results demonstrate deleterious effects of reducing EphA4 levels in juvenile mice and do not provide support for the hypothesis that widespread EphA4 reduction is beneficial in the SOD1<sup>G93A</sup> mouse model of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dominguez</LastName><ForeName>Sara L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Genentech, Neuroscience, South San Francisco, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Earr</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Genentech, Neuroscience, South San Francisco, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dourado</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Genentech, Neuroscience, South San Francisco, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngu</LastName><ForeName>Hai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Genentech, Pathology, South San Francisco, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meilandt</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Genentech, Neuroscience, South San Francisco, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanson</LastName><ForeName>Jesse E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Genentech, Neuroscience, South San Francisco, 94080, USA. jesseeh@gene.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D036122">Receptor, EphA4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036122" MajorTopicYN="N">Receptor, EphA4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32973290</ArticleId><ArticleId IdType="pmc">PMC7515861</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-72723-y</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-72723-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dion PA, Daoud H, Rouleau GA. Genetics of motor neuron disorders: New insights into pathogenic mechanisms. Nat. Rev. Genet. 2009;10:769&#x2013;782. doi: 10.1038/nrg2680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg2680</ArticleId><ArticleId IdType="pubmed">19823194</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoecke A, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat. Med. 2012;18:1418&#x2013;1422. doi: 10.1038/nm.2901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2901</ArticleId><ArticleId IdType="pubmed">22922411</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu AK, et al. Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. Proc. Natl. Acad. Sci. U S A. 2014;111:9959&#x2013;9964. doi: 10.1073/pnas.1405803111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1405803111</ArticleId><ArticleId IdType="pmc">PMC4103318</ArticleId><ArticleId IdType="pubmed">24958880</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas LM, et al. EphA4 activation of c-Abl mediates synaptic loss and LTP blockade caused by amyloid-beta oligomers. PLoS ONE. 2014;9:e92309. doi: 10.1371/journal.pone.0092309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0092309</ArticleId><ArticleId IdType="pmc">PMC3962387</ArticleId><ArticleId IdType="pubmed">24658113</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldshmit Y, Galea MP, Wise G, Bartlett PF, Turnley AM. Axonal regeneration and lack of astrocytic gliosis in EphA4-deficient mice. J. Neurosci. 2004;24:10064&#x2013;10073. doi: 10.1523/JNEUROSCI.2981-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2981-04.2004</ArticleId><ArticleId IdType="pmc">PMC6730186</ArticleId><ArticleId IdType="pubmed">15537875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemmens R, Jaspers T, Robberecht W, Thijs VN. Modifying expression of EphA4 and its downstream targets improves functional recovery after stroke. Hum. Mol. Genet. 2013;22:2214&#x2013;2220. doi: 10.1093/hmg/ddt073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt073</ArticleId><ArticleId IdType="pubmed">23418304</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B, et al. Potent and selective EphA4 agonists for the treatment of ALS. Cell Chem. Biol. 2017;24:293&#x2013;305. doi: 10.1016/j.chembiol.2017.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2017.01.006</ArticleId><ArticleId IdType="pmc">PMC6522132</ArticleId><ArticleId IdType="pubmed">28196613</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Cooper LT, Boyd AW, Bartlett PF. Decreased signalling of EphA4 improves functional performance and motor neuron survival in the SOD1(G93A) ALS mouse model. Sci. Rep. 2018;8:11393. doi: 10.1038/s41598-018-29845-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-29845-1</ArticleId><ArticleId IdType="pmc">PMC6065374</ArticleId><ArticleId IdType="pubmed">30061574</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling KK, et al. Antisense-mediated reduction of EphA4 in the adult CNS does not improve the function of mice with amyotrophic lateral sclerosis. Neurobiol. Dis. 2018;114:174&#x2013;183. doi: 10.1016/j.nbd.2018.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.03.002</ArticleId><ArticleId IdType="pubmed">29518482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rue L, et al. Reducing EphA4 before disease onset does not affect survival in a mouse model of amyotrophic lateral sclerosis. Sci. Rep. 2019;9:14112. doi: 10.1038/s41598-019-50615-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-50615-0</ArticleId><ArticleId IdType="pmc">PMC6773754</ArticleId><ArticleId IdType="pubmed">31575928</ArticleId></ArticleIdList></Reference><Reference><Citation>Dottori M, et al. EphA4 (Sek1) receptor tyrosine kinase is required for the development of the corticospinal tract. Proc. Natl. Acad. Sci. U S A. 1998;95:13248&#x2013;13253. doi: 10.1073/pnas.95.22.13248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.22.13248</ArticleId><ArticleId IdType="pmc">PMC23772</ArticleId><ArticleId IdType="pubmed">9789074</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai KO, Ip FC, Cheung J, Fu AK, Ip NY. Expression of Eph receptors in skeletal muscle and their localization at the neuromuscular junction. Mol. Cell Neurosci. 2001;17:1034&#x2013;1047. doi: 10.1006/mcne.2001.0997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/mcne.2001.0997</ArticleId><ArticleId IdType="pubmed">11414792</ArticleId></ArticleIdList></Reference><Reference><Citation>Deitch JS, et al. Phenotype of transgenic mice carrying a very low copy number of the mutant human G93A superoxide dismutase-1 gene associated with amyotrophic lateral sclerosis. PLoS ONE. 2014;9:e99879. doi: 10.1371/journal.pone.0099879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0099879</ArticleId><ArticleId IdType="pmc">PMC4063781</ArticleId><ArticleId IdType="pubmed">24945277</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Pichon CE, et al. EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS. PLoS ONE. 2013;8:e62342. doi: 10.1371/journal.pone.0062342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0062342</ArticleId><ArticleId IdType="pmc">PMC3637182</ArticleId><ArticleId IdType="pubmed">23638043</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Pichon, C. E. et al. Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Sci. Transl. Med.9, 10.1126/scitranslmed.aag0394 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28814543</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta-Ghosh A, et al. Muscle specific kinase (MuSK) activation preserves neuromuscular junctions in the diaphragm but is not sufficient to provide a functional benefit in the SOD1(G93A) mouse model of ALS. Neurobiol. Dis. 2019;124:340&#x2013;352. doi: 10.1016/j.nbd.2018.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.12.002</ArticleId><ArticleId IdType="pubmed">30528255</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaastra B, et al. Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 2016;17:593&#x2013;599. doi: 10.1080/21678421.2016.1213852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1213852</ArticleId><ArticleId IdType="pmc">PMC5125285</ArticleId><ArticleId IdType="pubmed">27584932</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen, W. et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet.48, 1043&#x2013;1048, 10.1038/ng.3622 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph. Lateral Scler. 2010;11:38&#x2013;45. doi: 10.3109/17482960903545334.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903545334</ArticleId><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozniak CD, et al. Dual leucine zipper kinase is required for excitotoxicity-induced neuronal degeneration. J. Exp. Med. 2013;210:2553&#x2013;2567. doi: 10.1084/jem.20122832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20122832</ArticleId><ArticleId IdType="pmc">PMC3832926</ArticleId><ArticleId IdType="pubmed">24166713</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>